Research Article|Articles in Press, 103652

The Italian registry of therapeutic apheresis: year of activity 2021

Published:February 06, 2023DOI:


      In 2019, the Italian National Blood Center (NBC), at the request of the Italian Scientific Society of Haemapheresis and Cell Manipulation (SIdEM), included the Italian Registry of Therapeutic Apheresis (IRTA) in the Information System of Transfusion Services (SISTRA), whose activity is coordinated by the NBC.
      The IRTA provides institutions and scientific societies with a wide range of information including therapeutic procedures and outcomes of treated patients.
      The Italian National Health Service offers therapeutic apheresis for patients with various conditions, but it is mainly the patient with haematological and/or neurological disorders who turns to the apheresis centres as evidenced by the activity data of 2021. In the haematological field, the apheresis centres mainly supply haematopoietic stem cells for autologous or allogeneic transplantation as well as mononuclear cell collection for extracorporeal photopheresis (ECP), a therapeutic approach of II line in post-transplant Graft versus Host Disease.
      The activity of 2021 in the neurological field confirms the data of 2019, the pre-pandemic year, and indicates that myasthenia, chronic inflammatory demyelinating polyneuropathy and Guillain-Barré syndrome along with other neurological pathologies related to immune disorders are the diseases in which apheresis procedures are most used.
      In conclusion, the IRTA is a valuable tool for monitoring the activity of apheresis centres carried out at a national level and above all for providing an overall picture of how the use of this therapeutic tool evolves and changes over time.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Catalano L., Piccinini V., Pati I., Masiello F, Barone F., Marano G., et al. 2021: Activity data, haemovigilance and epidemiological surveillance Roma: Istituto Superiore di Sanità; 2022 (Rapporti ISTISAN 22/25) 88pp.

        • de Silvestro G.
        • Catalano L.
        • Marano G.
        • Piccinini V.
        • Pupella S.
        • Ostuni A.
        • et al.
        The Italian registry of therapeutic apheresis enters the information system of transfusion services –SISTRA.
        Transfus Apher Sci. 2022; 61: 1-8
        • Padmanabhan A.
        • Padmanabhan L.
        • Aqui N.
        • Balogun R.A.
        • Klingel R.
        • Meyer E.
        • et al.
        Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the american society for apheresis: the eighth special issue.
        J Clin Apher. 2019; 34: 171-354
        • Maddur M.S.
        • Othy S.
        • Hegde P.
        • Vani J.
        • Lacroix-Desmazes S.
        • Bayry J.
        • et al.
        Immunomodulation by intravenous immunoglobulin: role of regulatory T cells.
        J Clin Immunol. 2010; 1 (Suppl): 84-88
        • Norris P.A.A
        • Kaur G
        • Lazarus A.H.
        New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases.
        Curr Opin Hematol. 2020; 27: 392-398
        • N’kaoua E.
        • Attarian S.
        • Delmont E.
        • Campana-Salort E.
        • Verschueren A.
        • Grapperon A.M.
        • et al.
        Immunoglobulin shortage: Practice modifications and clinical outcomes in a reference centre.
        Rev Neurol. 2022; 178: 616-623
        • Sasongko P.L.
        • van Kraaij M.
        • So-Osman C.
        Using a scenario approach to assess for the current and future demand of immunoglobulins: an interview and literature study from The Netherlands.
        Transfus Med. 2022; : 1-12
      2. Di Giorgio D., Traversa G., Trotta M.P. et al. Guideline on the use of human immunoglobulins in case of shortages 〈〉 2022 Feb;1–33.